Semin Reprod Med 2008; 26(1): 121-126
DOI: 10.1055/s-2007-992932
© Thieme Medical Publishers

In Vitro Maturation for Patients with Polycystic Ovary Syndrome

Shauna L. Reinblatt1 , William Buckett1
  • 1Department of Obstetrics and Gynecology, McGill University, Royal Victoria Hospital, Montreal, Quebec, Canada
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
08. Januar 2008 (online)

Preview

ABSTRACT

In vitro fertilization (IVF) with ovarian stimulation is an effective treatment for couples needing treatment with assisted reproductive technologies (ART) where polycystic ovary syndrome (PCOS) is coexisting. However, it is also associated with an increased risk of ovarian hyperstimulation syndrome.

In vitro maturation (IVM) avoids the risks and side effects of ovarian stimulation by retrieving immature oocytes from unstimulated ovaries. These immature oocytes are then cultured, matured, and fertilized in vitro. Embryos are then selected for transfer in the same manner as conventional IVF. Although there has been significant progress in terms of improving clinical pregnancy and live-birth rates after IVM, there remains much to learn in terms of what controls maturation, fertilization, and implantation rates. This review is intended as an update on the most recent advances and directions of ongoing research in IVM in patients with PCOS.

REFERENCES

William BuckettM.D. 

Department of Obstetrics and Gynecology, McGill University, Royal Victoria Hospital

687 Pine Avenue West, Montreal, Quebec H3A 1A1, Canada

eMail: william.buckett@muhc.mcgill.ca